Aer Therapeutics, Inc.
Rich Franco is a seasoned professional currently serving as Head of Operations and Strategy at Aer Therapeutics, Inc., where responsibilities include leading regulatory, CMC, and corporate operations since May 2023. Additionally, Franco has held the position of Chief Regulatory Officer at Eiger BioPharmaceuticals since April 2016, overseeing development and regulatory activities for several key products, including Zokinvy (lonafarnib) and various projects related to lonafarnib HDV, Lambda Covid, Lambda HDV, and Avexitide PBH/CHI.
This person is not in any teams
This person is not in any offices
Aer Therapeutics, Inc.
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on treating respiratory diseases with significant unmet need, such as COPD, cystic fibrosis and asthma. Our technology was developed and spun out of Dr. John Fahy’s airway biology lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.